2023 World Conference on Lung Cancer (Posters)-EP07.02. Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer:A Multi-center Survey of Current Practice from China

EP07.02. Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer:A Multi-center Survey of Current Practice from China - PDF(Slides)

Back to course

Pdf Summary

A survey was conducted in China to investigate the impact of neoadjuvant immunotherapy on surgical practice for non-small cell lung cancer (NSCLC). The survey included 267 responses from thoracic surgeons across 27 provinces. The majority of surgeons had more than 10 years of experience and worked in high-volume centers.<br /><br />The most common setting for neoadjuvant immunotherapy was central NSCLC of stage III. Surgeons considered tumor size, lymph node metastasis, and probability of R0 resection when deciding on neoadjuvant immunotherapy. Surgery was typically performed 4-6 weeks after the completion of immunotherapy, with lobectomy being the most common type of surgery.<br /><br />Surgeons reported observing immune-related adverse events in 45% of cases, and this was more common in experienced surgeons. There were variations in opinions regarding the difficulty of surgery after neoadjuvant immunotherapy, with 32% of surgeons reporting increased difficulty, 32% reporting comparable difficulty, and 29% believing that the difficult cases became harder and the easy cases became easier. However, most surgeons agreed that neoadjuvant immunotherapy did not increase the risk of intraoperative or postoperative major adverse events.<br /><br />Overall, neoadjuvant immunotherapy was found to result in acceptable adverse events, enhance resectability, and not increase the complexity of surgery for most experienced surgeons. The findings of this survey highlight the variations in surgical management preferences among thoracic surgeons in China.

Asset Subtitle

Han Wu

Meta Tag

Speaker Han Wu

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

neoadjuvant immunotherapy

surgical practice

NSCLC

survey

thoracic surgeons

tumor size

lymph node metastasis

lobectomy

adverse events

surgical management